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Introduction
The sympathetic nervous system regulates heart rate (HR) and cardiac contractility through release of catecholamines acting on β-adrenoceptors (β-ARs). Within the heart three different β-ARs exist, the β 1 -, β 2 -and β 3 -AR subtypes (Wilson & Lincoln, 1984) , with each having their specific signalling pathway and function (Altan et al. 2007) . In many cardiomyopathies, the contractile (inotropic) effect of non-specific β-AR stimulation is reduced, which in heart failure has been attributed to downregulation of the β 1 -AR subtype (Bristow et al. 1982) and intracellular redistribution of the β 2 -AR subtype (Nikolaev et al. 2010) .
Importantly, cardiac output, as a measure of heart function, is determined not only by contractility of the heart, but also by regulation of HR (chronotropy). Chronotropy is initiated by specialized cardiomyocytes within the sinoatrial node located in the right atrium (Monfredi et al. 2013) . Almost three decades ago the Framingham Study (Kannel et al. 1987) showed that resting HR was the strongest predictor of mortality in patients with cardiac disease, an association that has since been proved (Nauman et al. 2011) . Impaired HR responses are also associated with exercise intolerance and increased all-cause mortality in patients with diabetes (Ho et al. 2008) . These studies all emphasize that chronotropic incompetence, which is an undervalued feature of the diabetic heart (Brubaker & Kitzman, 2011) , might be as important as inotropic dysfunction in diabetes. We recently showed that type 2 diabetes in rats have reduced intrinsic HR, which might be a compensatory adaptation that is associated with elevated cardiac sympathetic nerve activity (Thaung et al. 2015) . Interestingly, β-AR blockers are used widely in the clinic but are less effective at reducing HR in type 2 diabetic patients and, notably, impair glucose control (Haas et al. 2003) . Although these data seem counterintuitive, regulation of HR in rodents is under sympathetic dominance, whereas in humans it is under parasympathetic dominance. Thus, despite species differences, impairment or dysregulation of resting and autonomic control of HR has major consequences for cardiovascular homeostasis in diabetes.
The specific contributions of the β 1 -and β 2 -AR subtypes to in vivo cardiovascular control, and specifically chronotropic regulation in type 2 diabetes, are unknown. Addressing this issue will not only improve our physiological understanding of sympathetic HR regulation in general, but will also provide vital information for understanding the pathological basis of HR dysregulation in type 2 diabetes. This is essential to improve current therapeutic strategies (β-AR blockers) and could also contribute to the understanding of potential new therapeutics, such as β-adrenergic receptor kinase carboxyl-terminus (β-ARKct; Rengo et al. 2011 ) and renal denervation (Schlaich et al. 2009 ).
Therefore, the aim of the present study was to investigate the specific β-AR subtype contributions to chronotropic responses in type 2 diabetes in vivo. We hypothesized that the specific β 1 -AR (and β 2 -AR)-mediated chronotropic responses would be reduced in type 2 diabetic rats. To this end, type 2 diabetic Zucker diabetic fatty (ZDF) rats and their non-diabetic littermates were implanted with a vascular access port to inject intravenous drugs and a radiotelemetric transmitter to measure chronotropic responses in vivo, and we used pharmacological approaches to distinguish between specific β-AR subtype responses.
Methods

Ethical approval
All experiments were approved (AEC22-13) and conducted within the guidelines of the Animal Ethics Committee of the University of Otago, New Zealand, and adhered to the NZ Animal Welfare Act 1991, which complies with the US National Institutes of Health Guide for the Care and use of Laboratory Animals.
Dual surgical implantation of vascular access port and radiotelemetric transmitter
Twenty-week-old male type 2 diabetic Zucker Diabetic Fatty (ZDF fa/fa , n = 12) rats and their non-diabetic littermates (ZDF +/+ , n = 12) were used, which were originally sourced from Charles River Laboratories, after which and a colony was established at the University of Otago.
A vascular access port and a radiotelemetric transmitter were surgically implanted for stress-free administration of β-AR agonists and antagonists and to record arterial blood pressure (ABP) and derived heart rate (HR), respectively, as described previously (Bussey et al. 2014a,b) . In brief, tail vein blood samples were collected after an 8 h fast 2 days before surgery for determination of blood glucose and insulin. Analgesia (5 mg kg −1 carprofen; Norbrook Laboratories Ltd, Newry, UK) and antibiotic (30 mg kg −1 trimethoprim and sulphamethazine; Virbac, Carros, France) were provided immediately before surgery and for 2 days after surgery. Animals were anaesthetized with 2.5% isoflurane (Minrad Inc., Bethlehem, PA, USA) in oxygen 1 litre min −1 . An antibiotic eye ointment (Tricin R ; Jurox, Auckland, New Zealand) was used to lubricate the rodent's eyes to prevent them drying out during surgery. The left femoral vein was cannulated for drug administration via a vascular access port (Access Technologies, Chicago, IL, USA), and the port was placed between the scapulae for percutaneous access. β 1 -and β 2 -Adrenoceptor chronotropic contributions in diabetes Through an abdominal incision, the pressure tip of the radiotelemetric transmitter (Telemetry Research, Millar Instruments, Houston, TX, USA) was placed in the abdominal aorta via cannulation. Animals recovered for 10 days postsurgery before experimentation commenced. One-third of the animals did not complete the study because of surgical failure, postoperative complications or instrument failure; consequently, in vivo experiments were successfully completed in n = 8 per group. All animals were killed by anaesthetic overdose, through intra-peritoneal injection of 60 mg kg −1 pentobarbital (Provit, Canada), at the end of the experimental procedures.
In vivo β 1 -and β 2 -AR chronotropic responses After implantation and recovery, experiments were performed in a random order bi-weekly to ensure complete drug clearance, avoiding the potential desensitization of β-ARs. Experimental protocols initially involved telemetric recording of resting ABP measurements before needle insertion in the vascular access port, followed by sodium nitroprusside (SNP, 6.25 μg kg −1 ; nitric oxide donor) injection to evoke a baroreceptor response ascertaining cannula patency and drug delivery.
Thereafter, animals were exposed to doses of the non-specific β-AR agonist isoprenaline (0.1-300 μg kg −1 , at 10 min intervals) in a randomized order, in the presence or absence of the selective β 1 -AR antagonist atenolol (2000 or 8000 μg kg −1 ) and in the presence or absence of the selective β 1 -and β 2 -AR antagonist nadolol (4000 μg kg −1 ). Owing to variable pharmacokinetics, we also used a second pharmacological approach to evaluate β 2 -AR function. We determined the effects of administration of the selective β 2 -AR agonist fenoterol (0.1-300 μg kg −1 ), which was always in the presence of the selective β 1 -AR antagonist atenolol (2000 μg kg −1 ). This will be referred to as fenoterol stimulation in the following sections (fenoterol without atenolol was not tested). Selection of drug doses was based on our previous publications (Bussey et al. 2014a,b) or pilot experiments. All chemicals were sourced from Sigma-Aldrich, USA.
Heart rate was derived from ABP recordings (1 kHz sample frequency; LabChart R , ADInstruments, Dunedin, New Zealand) and averaged over 10 consecutive cardiac cycles. Heart rate data were assessed as the calculated change between the maximal response to each β-AR agonist administration and the baseline measurement preceding any injection of β-AR agonist. Time course profiles were assessed in consecutive 5 s averages. Time to peak HR was defined as the time elapsed between the baseline HR at drug injection and the peak HR. The HR recovery was defined as the time elapsed between peak HR and when HR returned to baseline. 
Statistical analysis
Data were recorded via a PowerLab 8/30 (ADInstruments, Dunedin, New Zealand) using the LabChart 7 blood pressure software. Student's unpaired t tests were used to test for differences between group characteristics. A two-way repeated-measures ANOVA was used to test for in vivo β-AR responsiveness comparisons. Differences between groups were identified using Student-Newman-Keuls post hoc analysis (Sigmaplot TM 12.0; Systat Software Inc., Chicago, IL, USA). For testing differences between groups with small sample sizes (n < 5) a Kolmogorov-Smirnov non-parametric test was used. A value of P < 0.05 was considered statistically significant. Results are expressed as means ± SD.
Results
Animal characteristics
The ZDF fa/fa rats had increased fasted blood glucose and insulin concentrations and a greater body weight than their ZDF +/+ littermates, confirming their type 2 diabetes and obese status (Table 1) . Heart weight, tibia length and their ratio were not different between groups. The type 2 diabetic rats experienced a lower basal resting in vivo HR (Table 1) , but not mean arterial pressure (MAP), compared with non-diabetic rats.
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Non-specific β-AR chronotropic responses in diabetes
Telemetric recordings provided continuous ABP measures, as demonstrated by representative raw traces of ABP from a control and a diabetic rat (Fig. 1A) , from which HR was calculated. Administration of the non-specific β-AR agonist isoprenaline elicited HR increases in both non-diabetic and diabetic rats that peaked 15 s after intravenous delivery and returned to basal rates within a 10 min period after injection of the agonist (Fig. 1A) . Concurrent with the increases in HR, a vasodilatory reflex response was observed, with a transient decrease in ABP (Fig. 1A) .
Average HR time courses after administration of three of the doses of the non-specific β-AR agonist isoprenaline in non-diabetic and diabetic rats are shown in Fig. 1B . Non-diabetic and diabetic rats did not differ in the time to peak isoprenaline response or the time taken to reach a stable plateau. However, after maximal β-AR stimulation, at 300 μg kg −1 isoprenaline, the time course of HR recovery from peak HR to resting values was prolonged in diabetic animals (non-diabetic 236 ± 80 s versus diabetic 519 ± 105 s, 300 μg kg −1 isoprenaline; P < 0.001). The maximal increases in HR after drug administrations are referred to as peak HR hereafter.
Conscious rats with diabetes required a greater β-AR agonist concentration to achieve a similar HR to the non-diabetic rats ( Fig. 2A) . However, at high doses of 100-300 μg kg −1 isoprenaline, HR in diabetic rats reached an equivalent peak HR to that of control rats, despite showing decreased resting HR ( Fig. 2A and Table 1 ). Accordingly, the absolute and relative change in HR from baseline was larger in rats with diabetes compared with non-diabetic rats at mid to high isoprenaline doses (10-300 μg kg −1 ) ( Fig. 2B and C) . Analysis of the ABP responses did not reveal any differences in MAP between the two groups ( Fig. 3A-C) .
Subtype-specific β-AR chronotropic responses in diabetes
To determine the specific β-AR subtype contributions, atenolol was used to block β 1 -AR responses. After administration of a clinical dose of atenolol (2000 μg kg −1 ), resting HR was lower in both non-diabetic and diabetic rats (Table 1) , suggestive of a role for β 1 -AR in the regulation of resting HR. Moreover, the β-AR-stimulated increases in HR were less sensitive in both non-diabetic and diabetic rats (Fig. 2D) . There was no difference in the dose-dependent absolute or relative change in HR between groups of animals following β 1 -AR blockade (Fig. 2E-F) . However, substantial chronotropic responses to high dose β-AR stimulation persisted following a clinical dose of atenolol ( Fig. 2E and F) , suggesting an incomplete β 1 -AR blockade. Accordingly, a supraclinical dose of β 1 -antagonist (atenolol 8000 μg kg −1 ) was administered to a smaller subgroup of animals, but β-AR chronotropic responsiveness between the control and diabetic animals remained similar at this dose ( Fig. 2G-I ), indicating that the increased β-AR chronotropic responsiveness in conscious rats with diabetes ( Fig. 2B and C) is regulated by the β 1 -AR. Analysis of the effect of atenolol on the MAP responses did not reveal any differences between the two groups ( Fig. 3D-F) .
Time courses of the HR response after administration of three of the isoprenaline doses in the presence of atenolol in non-diabetic and diabetic rats are shown Fig. 1C . The prolonged HR recovery in diabetes following maximal β-AR stimulation at 300 μg kg −1 isoprenaline was blunted by β 1 -AR blockade with atenolol ( Fig. 1C ; non-diabetic 257 ± 52 s versus diabetic 377 ± 69 s, 300 μg kg −1 isoprenaline, n.s.).
To determine the specific β-AR subtype contributions to HR regulation, nadolol, a β 1 -and β 2 -AR antagonist, was administered (4000 μg kg −1 ). Nadolol did not decrease resting HR further than sole β 1 -AR blockade with atenolol, suggesting an absence of β 2 -AR input in resting HR regulation in both non-diabetic and diabetic rats (Table 1) . Nadolol also completely blocked the isoprenaline-induced responses in HR at doses lower than 300 μg kg −1 isoprenaline ( Figs 1D and 4A ). The complete block of the β-AR-induced haemodynamic effects by administration of nadolol excludes involvement of the β 3 -AR subtype in chronotropic regulation. Moreover, it also supports the conclusion that the observed HR responses were attributed solely to β-AR stimulation and not to increases in blood volume or an injection-induced stress response, because the injection of eight saline boluses did not cause any significant change in HR (Fig. 4B) . Analysis of the ABP responses to nadolol did not reveal any differences in MAP between the two groups (data not shown).
Alternative pharmacological approach to assess specific β-AR subtype contribution
To minimize the impact of variable pharmacokinetics, a secondary pharmacological approach for evaluation of specific β-AR subtype contributions was applied. Fenoterol, known as a β 2 -AR agonist, was administered in the presence of atenolol to ensure that fenoterol stimulation was β 2 -AR specific. In all the experiments, atenolol was administered before fenoterol (referred to as fenoterol stimulation). Stimulation with the β 2 -AR agonist fenoterol produced the same pattern of response as isoprenaline (+ atenolol); that of an increase in HR and a decrease in MAP (Fig. 5A) . The time course of mean HR responses (Fig. 5B) , the averaged HR dose responses (Fig. 5C ) and the absolute and relative peak change in HR responses ( Fig. 5D and E) were increased with β 1 -and β 2 -Adrenoceptor chronotropic contributions in diabetes 
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In both non-diabetic (filled circles) and type 2 diabetic ZDF rats (open circles), incremental doses of β-AR agonist (isoprenaline) stimulated an increase in HR. A-C, type 2 diabetic ZDF rats required a higher isoprenaline concentration to achieve equivalent absolute HR, but high β-AR agonist stimulation resulted in equivalent absolute HR compared with non-diabetes rats (A); however, the absolute (B) and relative changes in HR (C) were increased in the type 2 diabetic ZDF rats. D-F, following a clinical dose of β 1 -AR antagonism (2000 μg kg −1 atenolol), the HRs elicited by isoprenaline stimulation were lower in type 2 diabetic compared with non-diabetic ZDF rats (D); however, the absolute (E) and relative increases in HR (F) were not different between groups. G-I, after a supraclinical dose of β 1 -AR antagonist (8000 μg kg −1 atenolol), isoprenaline stimulated increases in HR only at high agonist concentrations, which were reduced in type 2 diabetic ZDF rats compared with non-diabetic rats (G) and the absolute (H) and relative changes in HR (I) were not different between groups. The type 2 diabetic ZDF rats had a lower HR compared with non-diabetic littermates at rest. Two-way repeated-measures ANOVA; * significant versus baseline and # significant versus non-diabetes, both P < 0.05. n = 8 per group, except in G-I n = 4 per group. Data are shown as means ± SD.
incrementing β 2 -AR activation in both non-diabetic and diabetic rats. Although the increases in HR attributable to fenoterol are less compared with isoprenaline, it should be noted that comparison of absolute HR responses induced by isoprenaline ( Fig. 2D-F ) and fenoterol ( Fig. 5C-E) , both in the presence of atenolol, is not entirely appropriate because of the differences in potency for β-ARs between the two agonists. More importantly, the absolute and relative peak changes in HR were equivalent between groups at all doses of fenoterol ( Fig. 5D and E) , suggesting no significant change in HR responsiveness via the β 2 -AR subtype with diabetes.
Discussion
Our study was designed to investigate the specific contributions of the β-AR subtypes to HR regulation in type 2 diabetic rats in vivo. Using stress-free, untethered telemetric recordings, we found an increase in the overall β-AR chronotropic responsiveness in type 2 diabetic rats, which was attributable to the β 1 -AR subtype and accompanied by a delayed β 1 -AR-associated HR recovery. Furthermore, we showed that the β 1 -AR subtype (but not the β 2 -AR) contributes to the resting HR, an effect that is proportional in non-diabetic and diabetic rats.
β-Adrenergic receptor subtype regulation of resting HR in diabetes
In this study, we derived a calculated conscious HR from the direct recording of ABP and showed that resting HR is reduced by 17% in diabetic rats compared with non-diabetic rats, as also described by others (Fredersdorf et al. 2004; Thaung et al. 2015) . After β 1 -AR blockade with atenolol, resting HR decreased to a similar extent in both non-diabetic and diabetic rats, by 22 and 21% relative to basal HR, the equivalent of a decrease of 85 and 65 beats min −1 , respectively. This suggests that β 1 -ARs are proportionately involved in the regulation of resting HR in both group of rats, although the intrinsic HR, determined by the pacemaker cells in the sinoatrial node, might still differ between non-diabetic and diabetic rats. β 1 -Adrenergic receptor stimulation occurs via the release of noradrenaline from cardiac sympathetic nerve terminals or adrenaline from the adrenal gland, which act on β-ARs on pacemaker cells in the sinoatrial node to increase HR (Vinik & Ziegler, 2007) . Recently, we observed an increased expression of β 1 -ARs in the right atrium in type 2 diabetic ZDF rats (Thaung et al. 2015) ; however, it is unknown whether β 1 -AR subtype expression is altered in the sinoatrial node in diabetes in humans or in rats. After β 1 -AR blockade, resting HR remained 15% lower in the diabetic compared with the non-diabetic rats. Interestingly, non-specific β 1 -and β 2 -AR blockade with nadolol did not decrease HR any further in either group, nor did it alter the difference in resting HR between both groups. This indicates not only that inhibition of β 1 -ARs results in full β-AR blockade of resting HR in both groups, but also that β 2 -ARs are not involved in the regulation of resting HR, a new and unexpected finding.
β 2 -Adrenergic receptors are expressed heterogeneously in the heart, increasing in proportion to β 1 -ARs, from the ventricles to the atria (Brodde et al. 2001) . The are found at their densest in the sinoatrial node in humans (Rodefeld et al. 1996) and are localized to t-tubules in close proximity to L-type Ca 2+ channels and 'funny' channels in rabbits, which would facilitate automaticity (Barbuti et al. 2007 ). Moreover, we recently found a 20% increase in the expression of β 2 -ARs in the right atria of type 2 diabetic ZDF rats (Thaung et al. 2015) , and therefore we hypothesized that β 2 -ARs would be involved in regulation of resting HR. However, the functional data from the present study did not support our hypothesis and show no role for β 2 -AR in the regulation of resting HR in vivo, in either non-diabetic or diabetic rats. This could be a species-dependent effect; however, it might also indicate that β 2 -ARs do not directly regulate heart function but are more responsible for modulation of intracellular metabolic homeostasis (Li et al. 2010; Pérez-Schindler et al. 2011) . It also means that the remaining 12-15% lower HR in diabetics after full β-AR blockade must relate to other R. F. Cook and others adaptations in HR regulation in type 2 diabetes, such as in nodal specific channels and calcium signalling proteins (Monfredi et al. 2013; D'Souza et al. 2014) or metabolic conditions (Malone et al. 2007) , both of which have been shown to impact on intrinsic heart rate.
Thus, the present study provides new data showing that while resting HR is under some influence of β-AR stimulation, the reduction in HR seen in diabetic rats is regulated independently of dysfunctions in specific β-AR subtypes, owing to the proportionate contribution of β 1 -ARs and the absence of β 2 -AR involvement.
β-Adrenergic receptor subtype regulation of chronotropy response in diabetes
Given the higher expression of the β 2 -AR in the sinoatrial node (Rodefeld et al. 1996) and its co-localization to 'funny' channels (Barbuti et al. 2007 ), we expected the β 2 -AR to be involved in the regulation of HR; however, none of the combinations of β-AR agonists or antagonists revealed a β 2 -AR-stimulated regulation of β-AR chronotropic responsiveness in the normal or diabetic rats, which was solely mediated by the β 1 -AR subtype. Interestingly, the contributions of the β 1 -AR to , the absolute (D), absolute change (E) or relative change in MAP (F) between type 2 diabetic and non-diabetic rats were also similar. Two-way repeated-measures ANOVA; * significant versus baseline, P < 0.05. n = 8 per group. Data are shown as means ± SD. β 1 -and β 2 -Adrenoceptor chronotropic contributions in diabetes HR regulation were significantly increased in diabetic rats at higher doses of isoprenaline (>3 μg kg −1 ). There are several potential explanations for the increased chronotropic role of β 1 -AR in diabetic rats, with an obvious candidate being increased β 1 -AR protein expression. However, earlier studies found a substantial downregulation of β 1 -AR expression, predominantly in experimental models of severe type 1 diabetes and targeting the left ventricle (Dinçer et al. 2001; Bidasee et al. 2003; Altan et al. 2007) , an effect confirmed for the left ventricle in type 2 diabetic models (Haley et al. 2015; Thaung et al. 2015) . Recently, we described higher expression levels of β 1 -ARs in the right atria of ZDF rats (Thaung et al. 2015) . Moreover, the exact expression levels of β 1 -ARs specifically within the sinoatrial node in diabetes in humans and rats is unknown (Thaung et al. 2015) . Alternative explanations include changes in autonomic axo-axonal synapses (Hasan, 2013) , reorganization of sinoatrial heterogeneity at the neuro-myocardial interface (Giles, 2005) and altered compartmentalization of cAMP and phosphodiesterases (Logue & Scott, 2010) .
The abnormal HR recovery in diabetic rats after maximal β 1 -and β 2 -AR activation was comparable to prolonged HR recovery after exercise testing in diabetic patients (Seshadri et al. 2003) . Heart rate recovery is easily determined in patients, and attenuation of HR recovery has predicted mortality (Cole et al. 1999) . Furthermore, autonomic dysfunction in diabetes is reversible in the early stages with accurate glycaemic control (Burger et al. 1999) . Hence, it may be important to diagnose prolonged HR recovery in patients with diabetes with subclinical autonomic dysfunction, in order to be able to provide them with optimal glycaemic control.
Overall, these data suggest that future studies into chronotropic incompetence in diabetes should focus on expression of the β-AR subtypes in the sinoatrial node and also on the structural and functional changes in autonomic axo-axonal synapses and neuro-myocardial interaction. This would provide valuable mechanistic insight into HR regulation required to determine which specific β-AR blockers might be best to treat patients with diabetes and chronotropic incompetence.
Limitations
The non-restrained telemetric conscious recordings were limited in the lack of measurements of stroke volume, an indication of contractility. This restricted the present study to the investigation of the β 1 -and β 2 -AR contributions to chronotropy in vivo; however, it does not exclude β 1 -and β 2 -AR contributions to the inotropic dysfunction in diabetes. Importantly, our approach of measuring the β-AR subtype chronotropic responsiveness in conscious rats with type 2 diabetes and finding different results from the anaesthetized (Dinçer et al. 1998 ) and isolated heart (Durante et al. 1989) approaches indicates the relevance of our conscious integrated physiological measurements.
Previously, we showed overall preservation of chronotropic β-AR responsiveness in conscious rats with type 2 diabetes with reduced β-AR sensitivity at low agonist concentrations, which could be attributed to the different potencies of isoprenaline and dobutamine ( Bussey et al. 2014a) . Dobutamine also exerts α-AR cardiovascular effects along with β-AR stimulation, and α-AR responses are known to be different in type 2 diabetic rats (Burgdorf et al. 2006; Bussey et al. 2014a) , hence our reason for using isoprenaline in this study. This indicates that not only β-AR subtypes, but also α-AR subtypes (or a combination or both) should be considered for modulation of HR regulation or as potential therapeutic targets to address chronotropic incompetence in diabetic patients.
The β 3 -AR subtype has been shown to be involved in inotropic and lusitropic modulation of cardiac function in diabetic rats (Amour et al. 2007 ); however, we did not specifically test for involvement of the β 3 -AR subtype in chronotropic regulation because administration of nadolol, a β 1 -and β 2 -AR antagonist, completely blocked all β-AR-induced chronotropic effects.
Zucker diabetic fatty rats have a non-functional Lepr gene located on chromosome 5 that leads to the production of non-functional leptin receptors (Takaya et al. 1996) and also have an autosomal recessive transcriptional defect in their pancreatic β-cells (Griffen et al. 2001) . Consequently, the animals sense no satiety, become obese and develop hyperglycaemia and hyperinsulinaemia from 12 weeks of age (Paulsen et al. 2010 ). This rodent model recapitulates the clinical phenotype of type 2 diabetes with obesity.
Conclusions
We found that β-AR-stimulated changes in HR were greater in type 2 diabetic rats compared with those in non-diabetic animals, were accompanied by a delayed β 1 -AR-associated HR recovery, and that this more sensitive diabetic β-AR chronotropic responsiveness was related to the β 1 -AR subtype. Moreover, the resting HR in diabetic rats remained under control of β 1 -ARs, but not β 2 -ARs, and was also regulated independently of dysfunctions in β-AR subtypes.
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